Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glypican 5 is an interferon-beta response gene: a replication study.

Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Aug 2009

Cénit M D C, Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha E G, Urcelay E, Arroyo R, Martínez A

Abstract excerpt

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Interferon-beta is the most usual therapy in relapsing-remiting MS. However, approximately 50% of the treated patients do not respond adequately. Very recently, a genome-wide association study on interferon-beta pharmacogenetics has described polymorphisms at several genes that are associated with response to this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disability Evaluation
Share to Extracellular Matrix Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glypicans

Share to Immunologic Factors

Share to Interferon-beta

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Proteoglycans

Share to Recurrence

Source

Identifiers

PMID: 19556317
DOI: 10.1177/1352458509106509

Genes

GPC5
HAPLN1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glypican 5 is an interferon-beta response gene: a replication study.PMID 19556317Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.Semantic proximity Read ↗

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.Semantic proximity Read ↗

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.Semantic proximity Read ↗

Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study.Semantic proximity Read ↗

Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes.Semantic proximity Read ↗

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Prediction of response to interferon therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?Semantic proximity Read ↗

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.